Bicara Therapeutics (BCAX) CEO Cohlhepp sold 17,500 shares for $401K at an average $22.90 under a 10b5-1 plan
Insider transactions reported
Ryan Cohlhepp (President, COO & Interim CEO at Bicara Therapeutics Inc., BCAX) reported that they sold 17,500 shares for $401K at an average $22.90, and acquired 17,500 shares at $3.79 on Sep 8, 2026. After these transactions the filing shows 181,641 shares held directly.
- Reporting person
- Cohlhepp Ryan
- Role
- President, COO & Interim CEO
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +17,500 | $3.79 | $66.3K | 199,141 direct |
| Sep 8, 2026 | Open-market sale (S) | Common Stock1, 2, 3 | -17,500 | avg $22.90 | $401K | 181,641 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 17,500 Common Stock1, 4 | -17,500 | - | - | 34,252 direct |
Holdings before and after
- Stock Option (Right to Buy): 51,752 to 34,252 direct
Footnotes from the filing
- 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.26 to $23.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- 4. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Cohlhepp report in this BCAX Form 4?
Ryan Cohlhepp (President, COO & Interim CEO at Bicara Therapeutics Inc., BCAX) reported that they sold 17,500 shares for $401K at an average $22.90, and acquired 17,500 shares at $3.79 on Sep 8, 2026. After these transactions the filing shows 181,641 shares held directly.
How many BCAX shares does Cohlhepp hold after this filing?
The filing shows 181,641 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this BCAX insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for BCAX
Across the 28 sessions after earlier BCAX headlines, the stock closed higher 15 times and lower 13 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BCAX | SPY |
|---|---|---|---|
| Sep 3, 2026 | Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | -0.9% | +1.0% |
| Aug 19, 2026 | BMO Capital Markets initiated coverage on Bicara Therapeutics with a new price target | +3.8% | +0.2% |
| Aug 14, 2026 | Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | +2.8% | -0.2% |
| Aug 11, 2026 | Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | -14.3% | -0.3% |
| Aug 4, 2026 | Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | +1.4% | +1.8% |
| Jul 28, 2026 | Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors | -3.3% | +0.2% |
Earlier insider filings at BCAX
- Aug 14, 2026SEC Form 4 filed by Chief Financial Officer Larson Jennifer
- Aug 12, 2026President and COO Cohlhepp Ryan exercised 18,750 shares at a strike of $3.79 and sold $524,533 worth of shares (18,750 units at $27.98) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 12, 2026Chief Executive Officer Mazumdar Claire exercised 10,000 shares at a strike of $3.79 and sold $279,750 worth of shares (10,000 units at $27.98) as part of a pre-agreed trading plan (SEC Form 4)
- Aug 12, 2026Chief Financial Officer Hyep Ivan sold $349,591 worth of shares (12,500 units at $27.97) as part of a pre-agreed trading plan and exercised 12,500 shares at a strike of $3.79 (SEC Form 4)
- Jul 29, 2026SEC Form 4 filed by Director Bender Jeremy
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Follow BCAX and get a push notification the moment its next story breaks.